Skip Navigation

Profile

Karl-Erik Andersson, M.D., Ph.D.Wake Forest School of Medicine

Karl-Erik Andersson, M.D., Ph.D.

Professor,


Contact Information

Academic: 336-713-1195

Email: keanders@wakehealth.edu

Education & Training

  • M.D., Lund University Fac Med-Sweden, 1968
Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Physiology & Pharmacology
Urology

Research Interests

Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Muscarinic Antagonists
More »

Contact Information

Academic: 336-713-1195

Email: keanders@wakehealth.edu

Recent Publications

The Clock mutant mouse is a novel experimental model for nocturia and nocturnal polyuria. Ihara T, Mitsui T, Nakamura Y, Kira S, Miyamoto T, Nakagomi H, Sawada N, Hirayama Y, Shibata K, Shigetomi E, Shinozaki Y, Yoshiyama M, Andersson KE, Nakao A, Takeda M, Koizumi S.. Neurourol Urodyn. 2017;36(4):1034-1038.

Clock genes regulate the circadian expression of Piezo1, TRPV4, Connexin26, and VNUT in an ex vivo mouse bladder mucosa. Ihara T, Mitsui T, Nakamura Y, Kira S, Nakagomi H, Sawada N, Hirayama Y, Shibata K, Shigetomi E, Shinozaki Y, Yoshiyama M, Andersson KE, Nakao A, Takeda M, Koizumi S.. PLoS One. 2017;12(1):e0168234.

Bladder capacity is a biomarker for a bladder-centric versus systemic manifestation in interstitial cystitis/bladder pain syndrome. Walker SJ, Zambon J, Andersson KE, Langefeld C, Matthews CA, Badlani G, Bowman H, Evans RJ.. J Urol. 2017;198(2):369-374.

Regenerative pharmacology in urology [editorial]. Andersson KE, Williams JK.. Investig Clin Urol. 2017;58(2):79-81.

Association of lower urinary tract syndrome with peripheral arterial occlusive disease. Lin WY, Andersson KE, Lin CL, Kao CH, Wu HC.. PLoS One. 2017;12(3):e0170288.

On the site and mechanism of action of beta3-adrenoceptor agonists in the bladder. Andersson KE.. Int Neurourol J. 2017;21(1):6-11.

Evaluating the procedure for performing awake cystometry in a mouse model [video article]. Mann-Gow TK, Larson TR, Woien CT, Andersen TM, Andersson KE, Zvara P.. J Vis Exp. 2017;(123):.

Characterization of a murine model of bioequivalent bladder wound healing and repair following subtotal cystectomy. Zarifpour M, Andersson KE, Kelkar SS, Mohs A, Mendelsohn C, Schneider K, Marini F, Christ GJ.. Biores Open Access. 2017;6(1):35-45.

Re: Inhibition of cholinergic neurotransmission by beta3-adrenoceptors depends on adenosine release and A1 receptors activation in human and rat urinary bladders [editorial]. Andersson KE.. Eur Urol. 2017;72(4):650-651.

Drugs for the overactive bladder: are there differences in persistence and compliance? [editorial]. Andersson KE.. Transl Androl Urol. 2017;6(3):597-601.

Chronic spinal cord injury causes upregulation of serotonin (5-HT)2A and 5-HT2C receptors in lumbosacral cord motoneurons. Cao N, Ni J, Wang X, Tu H, Gu B, Si J, Wu G, Andersson KE.. BJU Int. 2017;():.

Efficacy and initial safety profile of CXCL12 treatment in a rodent model of urinary sphincter deficiency. Koudy Williams J, Dean A, Lankford S, Andersson KE.. Stem Cells Transl Med. 2017;6(8):1740-1746.

Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction. Aizawa N, Ichihara K, Fukuhara H, Fujimura T, Andersson KE, Homma Y, Igawa Y.. Sci Rep. 2017;7(1):7646.

Results of a phase 1B multicenter study evaluating the safety and potential activity of two escalating doses of HMAXI-K gene transfer by direct infection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder. Chai T, Rovner E, Jacobs S, Christ G, Andersson K, Efros M, Nitti V, Melman A.. Neurourol Urodyn. 2017;36(Suppl 3):S46-S48.

Oxidative stress and its possible relation to lower urinary tract functional pathology. Andersson KE.. BJU Int. 2017;():.

Melatonin improves erectile function in rats with chronic lower body ischemia. Sawada N, Nomiya M, Zarifpour M, Mitsui T, Takeda M, Andersson KE.. J Sex Med. 2016;13(2):179-186.

Potential future pharmacological treatment of bladder dysfunction. Andersson KE.. Basic Clin Pharmacol Toxicol. 2016;119(Suppl 3):75-85.

Cell versus chemokine therapy in a nonhuman primate model of chronic intrinsic urinary sphincter deficiency. Williams JK, Dean A, Badra S, Lankford S, Poppante K, Badlani G, Andersson KE.. J Urol. 2016;196(6):1809-1815.

Regenerative medicine therapies for stress urinary incontinence. Williams JK, Dean A, Badlani G, Andersson KE.. J Urol. 2016;196(6):1619-1626.

Re: Nonantimuscarinic treatment for overactive bladder: a systematic review [editorial]. Andersson KE.. Eur Urol. 2016;70(6):1077.

Local versus intravenous injections of skeletal muscle precursor cells in nonhuman primates with acute or chronic intrinsic urinary sphincter deficiency. Williams JK, Badlani G, Dean A, Lankford S, Poppante K, Criswell T, Andersson KE.. Stem Cell Res Ther. 2016;7(1):147.

Tramadol abuse and sexual function. Abdel-Hamid IA, Andersson KE, Waldinger MD, Anis TH.. Sex Med Rev. 2016;4(3):235-246.

Regenerative pharmacology: recent developments and future perspectives. Williams JK, Andersson KE.. Regen Med. 2016;11(8):859-870.

Pharmacologic management of lower urinary tract storage and emptying failure. Andersson KE, Wein AJ. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, eds. Campbell-Walsh urology. 11th ed. Philadelphia (PA): Elsevier;2016: .

Intraprostatic injections for lower urinary tract symptoms treatment. Andersson KE.. Curr Opin Urol. 2015;25(1):12-18.

Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Zarifpour M, Nomiya M, Sawada N, Andersson KE.. Prostate. 2015;75(3):233-241.

Mechanisms of ATP release - future therapeutic targets? [editorial]. Andersson KE.. BJU Int. 2015;115(6):850-851.

Potential of stem cell treatment in detrusor dysfunction. Andersson KE.. Adv Drug Deliv Rev. 2015;82-83():117-122.

Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Nomiya M, Andersson KE, Yamaguchi O.. Int J Urol. 2015;22(1):40-46.

Chronic pelvic ischemia: contribution to the pathogenesis of lower urinary tract symptoms (LUTS): a new target for pharmacological treatment?. Andersson KE, Nomiya M, Yamaguchi O.. Low Urin Tract Symptoms. 2015;7(1):1-8.

Urinary bladder mucosal responses to ischemia. Sunagawa M, Wolf-Johnston A, Nomiya M, Sawada N, Andersson KE, Hisamitsu T, Birder LA.. World J Urol. 2015;33(2):275-280.

Superoxide overproduction and kidney fibrosis: a new animal model. Guimaraes-Souza NK, Yamaleyeva LM, Lu B, Ramos AC, Bishop CE, Andersson KE.. Einstein (Sao Paulo). 2015;13(1):79-88.

Alpha1 -adrenergic receptors mediate bladder overactivity induced by cold stress in rats with bladder outlet obstruction. Yamagishi T, Ishizuka O, Imamura T, Yokoyama H, Ogawa T, Kurizaki Y, Nishizawa O, Andersson KE.. Neurourol Urodyn. 2015;34(3):280-285.

Serotonin (5-HT)2A/2C receptor agonist (2,5-dimethoxy-4-idophenyl)-2-aminopropane hydrochloride (DOI) improves voiding efficiency in the diabetic rat. Tu H, Cao N, Gu B, Si J, Chen Z, Andersson KE.. BJU Int. 2015;116(1):147-155.

Drug therapy of overactive bladder - what is coming next?. Andersson KE.. Korean J Urol. 2015;56(10):673-679.

The potential utility of non-invasive imaging to monitor restoration of bladder structure and function following subtotal cystectomy (STC). Burmeister D, Bishwokarma B, AbouShwareb T, Olson J, Herco M, Tan J, Andersson KE, Christ G.. BMC Urol. 2015;15(1):103.

Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor. Fullhase C, Hennenberg M, Sandner P, Strittmatter F, Niedworok C, Bauer RM, Gratzke C, Soler R, Stief C, Andersson KE.. Neurourol Urodyn. 2015;34(8):787-793.

Translational research and functional changes in voiding function in older adults. Kullmann FA, Birder LA, Andersson KE.. Clin Geriatr Med. 2015;31(4):535-548.

Differentiated adipose-derived stem cells for bladder bioengineering. Salemi S, Tremp M, Plock JA, Andersson KE, Gobet R, Sulser T, Eberli D.. Scand J Urol. 2015;49(5):407-414.

What's going on the the overactive bladder arena?. Andersson KE.. Drugs Future. 2015;40(12):827-834.

Lamina propria: the functional center of the bladder?. Andersson KE, McCloskey KD.. Neurourol Urodyn. 2014;33(1):9-16.

Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome. Chapple CR, Abrams P, Andersson KE, Radziszewski P, Masuda T, Small M, Kuwayama T, Deacon S.. J Urol. 2014;191(1):253-260.

Functional consequences of chronic bladder ischemia. Yamaguchi O, Nomiya M, Andersson KE.. Neurourol Urodyn. 2014;33(1):54-58.

Bladder function in a cannabinoid receptor type 1 knockout mouse. Fullhase C, Campeau L, Sibaev A, Storr M, Hennenberg M, Gratzke C, Stief C, Hedlund P, Andersson KE.. BJU Int. 2014;113(1):144-151.

Bladder underactivity [editorial]. Andersson KE.. Eur Urol. 2014;65(2):399-401.

Effects of allogeneic bone marrow derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson disease. Campeau L, Soler R, Sittadjody S, Pareta R, Nomiya M, Zarifpour M, Opara EC, Yoo JJ, Andersson KE.. J Urol. 2014;191(3):850-859.

An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C.. Eur Urol. 2014;65(5):981-990.

Characterization of functional bladder regeneration in mice [abstract]. Zarifpour M, Sandberg J, Abolbashari M, Vadhavkar M, Kelkar S, Mohs A, Marini F, Andersson KE, Christ G.. Neurourol Urodyn. 2014;33(2):186.

Terminology, epidemiology, etiology, and pathophysiology of nocturia. Van Kerrebroeck P, Andersson KE.. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5.

Characterization of bladder function in a cannabinoid receptor type 2 knockout mouse in vivo and in vitro. Campeau L, Fullhase C, Sawada N, Gratzke C, Hedlund P, Howlett AC, Andersson KE.. Neurourol Urodyn. 2014;33(5):566-570.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Physiology & Pharmacology
Urology

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Six Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsMagnet Hospital RecognitionJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.